# MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients

Source: https://onco.cc/trials/nct04651634/  
OnCo record `nct04651634` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of MIT-001 plus CCRT in head and neck squamous cell carcinoma, run by MitoImmune Therapeutics, active and no longer recruiting.

## Summary

MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients is a phase 2 interventional study registered as NCT04651634 by MitoImmune Therapeutics, with 60 participants enrolled, started 2021-06-21 and due to reach its primary completion in 2025-12-31. Interventions recorded: MIT-001 plus CCRT.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04651634
- Phase: 2
- Setting: A Phase 2, Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of MIT-001 in Prevention of Oral Mucositis in Patients Receiving CCRT for Locally Advanced HNSCC
- Sponsor: MitoImmune Therapeutics
- Enrolled: 60

## Sources

- ClinicalTrials.gov NCT04651634: https://clinicaltrials.gov/study/NCT04651634

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)

---
JSON: https://onco.cc/api/v1/entities/nct04651634.json